The Clinical Pharmacokinetics of Pyrazinamide in HIV-Infected Persons with Tuberculosis

David C. Perlman, Yoninah Segal, Susan Rosenkranz, Petrie M. Rainey, Charles A. Peloquin, Rory P. Remmel, Keith Chirgwin, Nadim Salomon, Richard Hafner

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

The pharmacokinetics of pyrazinamide (PZA) in patients with human immunodeficiency virus (HIV)-related tuberculosis are incompletely characterized. Serum PZA concentrations were determined at 2, 6, and 10 h after dosing in 48 subjects with HIV-related tuberculosis. Estimates of drug exposure using 2-h concentrations and 2- and 3-time point estimates of area under time-concentration curves (AUCs) were compared. For daily dosing, 2-h concentrations less than low and very low literature-defined cut points (i.e., 20 and 10 mg/L) were noted for 2 subjects (4%) and 1 subject (2%), respectively. For intermittent PZA dosing, 1 subject (4%) had a 2-h concentration that was less than the low cut point (25 mg/L). Correlations between 2-h concentration and AUC estimates based on 2- or 3-time point concentration determinations were strong. In HIV-infected persons receiving antituberculosis regimens containing PZA, lower-than-expected 2-h concentrations are uncommon. For therapeutic monitoring of PZA drug exposure, determination of a 2-h postdose concentration appears as reliable as 2- or 3-time point estimates of the AUC for PZA.

Original languageEnglish (US)
Pages (from-to)556-564
Number of pages9
JournalClinical Infectious Diseases
Volume38
Issue number4
DOIs
StatePublished - Feb 15 2004

Bibliographical note

Funding Information:
Financial support: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group (grants 1U01AI46370, UO1A127673, A12015802, A6201, A1802, A5802, A2205, AO603, A5901, A1701, A2503, #IUO1A13844, PHS NCRR MO1 RR05096, and AI 38855).

Fingerprint Dive into the research topics of 'The Clinical Pharmacokinetics of Pyrazinamide in HIV-Infected Persons with Tuberculosis'. Together they form a unique fingerprint.

Cite this